vs

Side-by-side financial comparison of EPR PROPERTIES (EPR) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.

EPR PROPERTIES is the larger business by last-quarter revenue ($181.3M vs $129.7M, roughly 1.4× Travere Therapeutics, Inc.). On growth, Travere Therapeutics, Inc. posted the faster year-over-year revenue change (73.4% vs 3.6%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 2.3%).

EPR Properties, formerly Entertainment Properties Trust, is a real estate investment trust based in Kansas City, Missouri, that invests in amusement parks, movie theaters, ski resorts, and other entertainment properties. It owns 353 properties as of 2022.

Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.

EPR vs TVTX — Head-to-Head

Bigger by revenue
EPR
EPR
1.4× larger
EPR
$181.3M
$129.7M
TVTX
Growing faster (revenue YoY)
TVTX
TVTX
+69.9% gap
TVTX
73.4%
3.6%
EPR
Faster 2-yr revenue CAGR
TVTX
TVTX
Annualised
TVTX
77.0%
2.3%
EPR

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
EPR
EPR
TVTX
TVTX
Revenue
$181.3M
$129.7M
Net Profit
$62.6M
Gross Margin
98.0%
Operating Margin
55.5%
-25.0%
Net Margin
34.5%
Revenue YoY
3.6%
73.4%
Net Profit YoY
845.8%
EPS (diluted)
$0.74
$0.04

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EPR
EPR
TVTX
TVTX
Q1 26
$181.3M
Q4 25
$182.9M
$129.7M
Q3 25
$182.3M
$164.9M
Q2 25
$178.1M
$114.4M
Q1 25
$175.0M
$81.7M
Q4 24
$177.2M
$74.8M
Q3 24
$180.5M
$62.9M
Q2 24
$173.1M
$54.1M
Net Profit
EPR
EPR
TVTX
TVTX
Q1 26
$62.6M
Q4 25
$66.9M
Q3 25
$66.6M
$25.7M
Q2 25
$75.6M
$-12.8M
Q1 25
$65.8M
$-41.2M
Q4 24
$-8.4M
Q3 24
$46.6M
$-54.8M
Q2 24
$45.1M
$-70.4M
Gross Margin
EPR
EPR
TVTX
TVTX
Q1 26
Q4 25
98.0%
Q3 25
99.0%
Q2 25
98.7%
Q1 25
94.3%
Q4 24
96.6%
Q3 24
97.4%
Q2 24
96.2%
Operating Margin
EPR
EPR
TVTX
TVTX
Q1 26
55.5%
Q4 25
56.8%
-25.0%
Q3 25
53.5%
15.1%
Q2 25
62.5%
-11.1%
Q1 25
58.1%
-52.2%
Q4 24
25.5%
-81.2%
Q3 24
51.4%
-89.3%
Q2 24
45.9%
-125.1%
Net Margin
EPR
EPR
TVTX
TVTX
Q1 26
34.5%
Q4 25
36.6%
Q3 25
36.5%
15.6%
Q2 25
42.5%
-11.1%
Q1 25
37.6%
-50.4%
Q4 24
-4.7%
Q3 24
25.8%
-87.1%
Q2 24
26.1%
-130.1%
EPS (diluted)
EPR
EPR
TVTX
TVTX
Q1 26
$0.74
Q4 25
$0.80
$0.04
Q3 25
$0.79
$0.28
Q2 25
$0.91
$-0.14
Q1 25
$0.78
$-0.47
Q4 24
$-0.19
$-0.71
Q3 24
$0.53
$-0.70
Q2 24
$0.51
$-0.91

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EPR
EPR
TVTX
TVTX
Cash + ST InvestmentsLiquidity on hand
$68.5M
$93.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3B
$114.8M
Total Assets
$5.7B
$605.2M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EPR
EPR
TVTX
TVTX
Q1 26
$68.5M
Q4 25
$90.6M
$93.0M
Q3 25
$13.7M
$110.9M
Q2 25
$13.0M
$75.2M
Q1 25
$20.6M
$61.9M
Q4 24
$22.1M
$58.5M
Q3 24
$35.3M
$36.4M
Q2 24
$33.7M
$32.3M
Total Debt
EPR
EPR
TVTX
TVTX
Q1 26
Q4 25
$2.9B
Q3 25
$2.8B
Q2 25
$2.8B
Q1 25
$2.8B
Q4 24
$2.9B
Q3 24
$2.9B
Q2 24
$2.8B
Stockholders' Equity
EPR
EPR
TVTX
TVTX
Q1 26
$2.3B
Q4 25
$2.3B
$114.8M
Q3 25
$2.3B
$73.6M
Q2 25
$2.3B
$32.7M
Q1 25
$2.3B
$32.8M
Q4 24
$2.3B
$59.1M
Q3 24
$2.4B
$-30.5M
Q2 24
$2.4B
$15.1M
Total Assets
EPR
EPR
TVTX
TVTX
Q1 26
$5.7B
Q4 25
$5.7B
$605.2M
Q3 25
$5.5B
$538.6M
Q2 25
$5.6B
$555.3M
Q1 25
$5.5B
$548.8M
Q4 24
$5.6B
$594.1M
Q3 24
$5.7B
$504.4M
Q2 24
$5.6B
$551.1M
Debt / Equity
EPR
EPR
TVTX
TVTX
Q1 26
Q4 25
1.26×
Q3 25
1.19×
Q2 25
1.20×
Q1 25
1.20×
Q4 24
1.23×
Q3 24
1.19×
Q2 24
1.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EPR
EPR
TVTX
TVTX
Operating Cash FlowLast quarter
$113.4M
$60.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.81×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EPR
EPR
TVTX
TVTX
Q1 26
$113.4M
Q4 25
$421.0M
$60.7M
Q3 25
$136.5M
$14.3M
Q2 25
$87.3M
$5.0M
Q1 25
$99.4M
$-42.2M
Q4 24
$393.1M
$-35.7M
Q3 24
$122.0M
$-42.5M
Q2 24
$78.7M
$-40.2M
Free Cash Flow
EPR
EPR
TVTX
TVTX
Q1 26
Q4 25
$269.2M
Q3 25
$132.1M
$14.2M
Q2 25
$82.4M
Q1 25
$84.7M
Q4 24
$129.2M
Q3 24
$121.5M
Q2 24
$71.3M
$-40.3M
FCF Margin
EPR
EPR
TVTX
TVTX
Q1 26
Q4 25
147.1%
Q3 25
72.5%
8.6%
Q2 25
46.3%
Q1 25
48.4%
Q4 24
72.9%
Q3 24
67.3%
Q2 24
41.2%
-74.5%
Capex Intensity
EPR
EPR
TVTX
TVTX
Q1 26
0.1%
Q4 25
82.9%
Q3 25
2.4%
0.1%
Q2 25
2.7%
Q1 25
8.4%
Q4 24
148.9%
Q3 24
0.3%
0.0%
Q2 24
4.2%
0.2%
Cash Conversion
EPR
EPR
TVTX
TVTX
Q1 26
1.81×
Q4 25
6.29×
Q3 25
2.05×
0.56×
Q2 25
1.15×
Q1 25
1.51×
Q4 24
Q3 24
2.62×
Q2 24
1.74×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EPR
EPR

Rental revenue$155.2M86%
Mortgage and other financing income$16.0M9%
Other$10.1M6%

TVTX
TVTX

FILSPARI$103.3M80%
Tiopronin Products$23.3M18%
License$3.1M2%

Related Comparisons